CRY2

Across TCGA pan-cancer cohorts, CRY2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRY2 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CRY2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRY2 expression acts as an unfavorable survival marker.

ACC, HNSC, and LUAD are the cancer types where CRY2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
HNSC	OS	Median	All	0.191	0.710	.021	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRY2–ACC (DFS)

Open the ACC breakdown →